Savant Capital LLC trimmed its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 55.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,222 shares of the biopharmaceutical company's stock after selling 7,706 shares during the quarter. Savant Capital LLC's holdings in Intra-Cellular Therapies were worth $520,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Eagle Asset Management Inc. grew its holdings in Intra-Cellular Therapies by 130.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company's stock worth $45,714,000 after buying an additional 353,723 shares in the last quarter. Franklin Resources Inc. grew its holdings in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock worth $129,463,000 after buying an additional 155,655 shares in the last quarter. Wasatch Advisors LP grew its holdings in Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after buying an additional 130,351 shares in the last quarter. M&G PLC bought a new position in Intra-Cellular Therapies in the 3rd quarter worth approximately $9,076,000. Finally, Westfield Capital Management Co. LP grew its holdings in Intra-Cellular Therapies by 11.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,159,356 shares of the biopharmaceutical company's stock worth $84,830,000 after buying an additional 116,494 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 2.60% of the company's stock.
Analysts Set New Price Targets
ITCI has been the subject of a number of recent analyst reports. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. JPMorgan Chase & Co. increased their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. StockNews.com began coverage on Intra-Cellular Therapies in a research report on Sunday. They set a "hold" rating on the stock. Finally, Piper Sandler reissued a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $103.62.
Check Out Our Latest Analysis on ITCI
Intra-Cellular Therapies Stock Performance
Shares of NASDAQ:ITCI traded up $0.64 during trading hours on Wednesday, hitting $128.60. 2,625,053 shares of the company's stock traded hands, compared to its average volume of 4,369,646. Intra-Cellular Therapies, Inc. has a 52 week low of $62.78 and a 52 week high of $128.75. The company's fifty day simple moving average is $108.45 and its two-hundred day simple moving average is $89.01. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72.
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
